Shots:

• The US FDA has approved Roszet for the treatment of elevated LDL-C in adult patients with primary non-familial hyperlipidemia and homozygous familial hypercholesterolemia
• The result showed a reduction of LDL cholesterol by 72% with 40mg/10mg dose and 64% with 10 mg/10mg dose. The level of LDL-reduction indicates from both the statin component i.e rosuvastatin reduces LDL cholesterol by 63% on the highest dose and 52% on 10 mg dose- and the ezetimibe component showed a reduction by 25% when added to statins
• Roszet (PO-qd) is available as combination tablet of 5mg/10mg- 10mg/10mg- 20mg/10mg and 40mg/10mg

  Ref: PRNewswire | Image: Business Wire